Developments in external beam radiotherapy for prostate cancer

Urology

Volumn 82, Issue 1, 2013, Pages 5-10

  Lumen, Nicolaas ^a   Ost, Piet ^a   Van Praet, Charles ^a   De Meerleer, Gert ^a   Villeirs, Geert ^a   Fonteyne, Valérie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; DRUG DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; LYMPH NODE METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW; TREATMENT INDICATION;

DOSE FRACTIONATION; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; SALVAGE THERAPY;

EID: 84879555764     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.03.043     Document Type: Review

References (65)

1. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
2. V. Fonteyne, N. Lumen, and G. Villeirs Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer Adv Urol 2012 2012 368528
3. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
4. G.A. Viani, E.J. Stefano, and S.L. Afonso Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials Int J Radiat Oncol Biol Phys 74 2009 1405 1418
5. M.J. Zelefsky, V.E. Reuter, and Z. Fuks Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer J Urol 179 2008 1368 1373 [discussion: 1373]
6. G.P. Swanson, M.A. Hussey, and C.M. Tangen Predominant treatment failure in postprostatectomy patients is local. analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2007 2225 2229
7. M. Bolla, H. van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial. 22911) Lancet 366 2005 572 578
8. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
9. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
10. T.N. Showalter, N. Ohri, and K.G. Teti Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy Int J Radiat Oncol Biol Phys 82 2012 e233 e238
11. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
12. B.J. Trock, M. Han, and S.J. Freedland Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
13. N. Ohri, A.P. Dicker, and E.J. Trabulsi Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling Eur J Cancer 48 2012 837 844
14. P. Bader, D. Echtle, and V. Fonteyne Prostate cancer pain management: EAU guidelines on pain management World J Urol 30 2012 677 686
15. N. Cellini, A.G. Morganti, and G.C. Mattiucci Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning Int J Radiat Oncol Biol Phys 53 2002 595 599
16. G. De Meerleer, G. Villeirs, and S. Bral The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy Radiother Oncol 75 2005 325 333
17. P. Ost, B. Speleers, and G. De Meerleer Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study Int J Radiat Oncol Biol Phys 79 2011 920 926
18. B. Pickett, E. Vigneault, and J. Kurhanewicz Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy Int J Radiat Oncol Biol Phys 44 1999 921 929
19. N. Housri, H. Ning, and J. Ondos Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer Int J Radiat Oncol Biol Phys 80 2011 614 620
20. V. Fonteyne, G. Villeirs, and B. Speleers Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion Int J Radiat Oncol Biol Phys 72 2008 799 807
21. E. Ippolito, G. Mantini, and A.G. Morganti Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity Am J Clin Oncol 35 2012 158 162
22. M. Pinkawa, M.D. Piroth, and R. Holy Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost Radiat Oncol 7 2012 14 23
23. T.N. Eade, A.L. Hanlon, and E.M. Horwitz What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 68 2007 682 689
24. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 2008 1124 1129
25. J.F. Fowler, M.A. Ritter, and R.J. Chappell What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56 2003 1093 1104
26. E.E. Yeoh, R.J. Botten, and J. Butters Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial Int J Radiat Oncol Biol Phys 81 2011 1271 1278
27. G. Arcangeli, J. Fowler, and S. Gomellini Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 79 2011 1013 1021
28. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
29. V. Fonteyne, G. Soete, and S. Arcangeli Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial Int J Radiat Oncol Biol Phys 84 2012 e483 e490
30. J.M. Martin, T. Rosewall, and A. Bayley Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma Int J Radiat Oncol Biol Phys 69 2007 1084 1089
31. C.R. King, and D.S. Kapp Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71 2008 346 350
32. A. Harrison, M. Studenski, and A. Harvey Potential for dose escalation in the postprostatectomy setting with intensity-modulated radiation therapy: a dosimetric study using EORTC consensus guidelines for target volume contours Pract Radiat Oncol 1 2011 105 114
33. P. Ost, C. Cozzarini, and G. De Meerleer High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy Int J Radiat Oncol Biol Phys 83 2012 960 965
34. P. Ost, V. Fonteyne, and G. Villeirs Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients Eur Urol 56 2009 669 675
35. C. Cozzarini, F. Montorsi, and C. Fiorino Need for high radiation dose (>or=70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients Int J Radiat Oncol Biol Phys 75 2009 966 974
36. R. Choo, C. Danjoux, and S. Gardner Prospective study evaluating postoperative radiotherapy plus. 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins Int J Radiat Oncol Biol Phys 75 2009 407 412
37. C. Cozzarini, C. Fiorino, and L.F. Da Pozzo Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients Int J Radiat Oncol Biol Phys 82 2012 191 199
38. J.R. Bernard Jr., S.J. Buskirk, and M.G. Heckman Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis Int J Radiat Oncol Biol Phys 76 2010 735 740
39. C.R. King, and M.T. Spiotto Improved outcomes with higher doses for salvage radiotherapy after prostatectomy Int J Radiat Oncol Biol Phys 71 2008 23 27
40. J.D. Cox, M.J. Gallagher, and E.H. Hammond Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel J Clin Oncol 17 1999 1155 1163
41. P. Ost, N. Lumen, and A.S. Goessaert High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results Eur Urol 60 2011 842 849
42. A. Goenka, J.M. Magsanoc, and X. Pei Long-term outcomes after high-dose postprostatectomy salvage radiation treatment Int J Radiat Oncol Biol Phys 84 2012 112 118
43. P. Bader, F.C. Burkhard, and R. Markwalder Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169 2003 849 854
44. M.C. Schumacher, F.C. Burkhard, and G.N. Thalmann Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy Eur Urol 54 2008 344 352
45. C. Cozzarini, A. Bolognesi, and G.L. Ceresoli Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients Int J Radiat Oncol Biol Phys 59 2004 674 683
46. L.F. Da Pozzo, C. Cozzarini, and A. Briganti Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy Eur Urol 55 2009 1003 1011
47. A. Briganti, R.J. Karnes, and L.F. Da Pozzo Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis Eur Urol 59 2011 832 840
48. A. Briganti, M.L. Blute, and J.H. Eastham Pelvic lymph node dissection in prostate cancer Eur Urol 55 2009 1251 1265
49. M. Roach 3rd, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
50. C.A. Lawton, M. DeSilvio, and M. Roach 3rd An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
51. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
52. V. Fonteyne, W. De Gersem, and W. De Neve Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer Int J Radiat Oncol Biol Phys 75 2009 1013 1020
53. S. Arcangeli, B. Saracino, and M.G. Petrongari Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area Radiother Oncol 84 2007 148 155
54. T.J. Robnett, R. Whittington, and S.B. Malkowicz Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer Int J Radiat Oncol Biol Phys 53 2002 1146 1151
55. C.A. Lawton, K. Winter, and D. Grignon Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31 J Clin Oncol 23 2005 800 807
56. Y. Furuya, K. Akakura, and S. Akimoto Pattern of progression and survival in hormonally treated metastatic prostate cancer Int J Urol 6 1999 240 244
57. A. Briganti, J.R. Karnes, and L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
58. O. Yossepowitch, F.J. Bianco Jr., and S.E. Eggener The natural history of noncastrate metastatic prostate cancer after radical prostatectomy Eur Urol 51 2007 940 947 [discussion: 947-948]
59. D. Singh, W.S. Yi, and R.A. Brasacchio Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58 2004 3 10
60. M. Picchio, E.G. Spinapolice, and F. Fallanca [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy Eur J Nucl Med Mol Imaging 39 2012 13 26
61. P. Berkovic, G. De Meerleer, and L. Delrue Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy Clin Genitourin Cancer 11 2013 27 32
62. F. Casamassima, L. Masi, and C. Menichelli Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients Tumori 97 2011 49 55
63. B.A. Jereczek-Fossa, G. Beltramo, and L. Fariselli Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer Int J Radiat Oncol Biol Phys 82 2012 889 897
64. P. Rigatti, N. Suardi, and A. Briganti Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography Eur Urol 60 2011 935 943
65. B.K. Chang, and R.D. Timmerman Stereotactic body radiation therapy: a comprehensive review Am J Clin Oncol 30 2007 637 644